NAGA
NAGA (alpha-N-acetylgalactosaminidase, also known as D22S674) is a lysosomal glycosidase that removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. It is required for glycolipid breakdown, and mutations in the NAGA gene cause Schindler disease. Browse Assay Genie's current range of NAGA research reagents below, or read on for the biology behind the target.
NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, a glycosidase that cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. It removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides, and this activity is required for the breakdown of glycolipids. The enzyme is classified as EC 3.2.1.49 and acts within the lysosome, where glycoconjugate degradation takes place.
The NAGA gene belongs to the HGNC group of alpha galactosidases, and the protein is a member of the glycosyl hydrolase 27 family. Orthologous genes are present in mouse and rat, both named Naga, which allows the enzyme to be studied in rodent models. The protein is also referred to as N-acetylgalactosaminidase, alpha-, and the gene was previously catalogued under the symbol D22S674.
NAGA has clear disease relevance. Mutations in the gene have been identified as the cause of Schindler disease types I and II, with type II also known as Kanzaki disease. Because loss of enzyme function affects the lysosomal handling of glycoconjugates, NAGA is a useful focus for researchers studying lysosomal storage disorders, glycolipid catabolism and glycosidase biology. Researchers working with the NAGA protein, whether through an NAGA antibody or an NAGA ELISA kit, can use it to examine these processes.
NAGA mutations cause Schindler disease types I and II, making the enzyme central to studies of this lysosomal disorder.
NAGA is required for the breakdown of glycolipids, so it is relevant to studies of how lysosomes degrade these molecules.
As a glycosyl hydrolase 27 family member cleaving terminal alpha-N-acetylgalactosamine, NAGA is a model for exoglycosidase specificity.
NAGA cleaves alpha-N-acetylgalactosaminyl groups from glycoconjugates, including glycopeptides, supporting work on glycan turnover.
NAGA is a lysosomal enzyme that removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. It cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates and is required for the breakdown of glycolipids. Its activity is classified under EC 3.2.1.49.
The HGNC full name is alpha-N-acetylgalactosaminidase. The previous name was N-acetylgalactosaminidase, alpha-, and the previous gene symbol was D22S674. The protein belongs to the glycosyl hydrolase 27 family and to the HGNC group of alpha galactosidases.
Yes. Mutations in NAGA cause Schindler disease types I and II, type II being known as Kanzaki disease. Mouse and rat both have an ortholog named Naga. Check the datasheet of any product for its validated reactivity.
Other lysosomal glycosidases and glycolipid-metabolism enzymes studied alongside NAGA.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P17050; product specifications from Assay Genie datasheets.